美沙拉嗪联合复方谷氨酰胺治疗溃疡性结肠炎的疗效

doi:10.3969/j.issn.1671-7171.2025.03.021

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1175 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨美沙拉嗪联合复方谷氨酰胺治疗溃疡性结肠炎(UC)的疗效。【方法】 102例UC患者,随机分为对照组与观察组,每组51例。对照组采用美沙拉嗪治疗,观察组采用美沙拉嗪联合复方谷氨酰胺治疗,比较两组治疗后结肠功能指标(腹胀、腹泻改善时间,大便次数及性状完全恢复时间),治疗前后肠黏膜屏障功能指标[二胺氧化酶(DAO)、D-乳酸水平]、炎症因子[肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)、白细胞介素-8(IL-8)、白细胞介素-10(IL-10)]水平及病变活跃度(肠黏膜病变评分、Mayo活动指数评分)。【结果】治疗前,两组患者各项指标比较,差异均无统计学意义(P>0.05);治疗后,观察组患者腹胀、腹泻改善时间,大便次数及性状完全恢复时间均显著短于对照组(P<0.05),观察组患者DAO、D-乳酸、TNF-α、CRP、IL-8水平及肠黏膜病变评分、Mayo活动指数评分均显著低于对照组,IL-10水平高于对照组(P<0.05)。【结论】美沙拉嗪联合复方谷氨酰胺治疗能够显著优化UC患者的结肠功能和病变活跃度,明显改善肠黏膜屏障功能,降低炎症因子水平。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	黄鹏
	梁晴晴
	王明超

关键词 ：结肠炎,溃疡性, 氨水杨酸, 谷氨酰胺, 治疗结果

Abstract：【Objective】To explore the efficacy of mesalazine combined with compound glutamine in the treatment of ulcerative colitis (UC).【Methods】 A total of 102 UC patients were randomly divided into a control group and an observation group, with 51 cases in each group. Patients in the control group received mesalazine treatment, while those in the observation group received mesalazine combined with compound glutamine. The outcomes, colonic function (improvement time in bloating, diarrhea, and complete recovery time of stool frequency and form/properties), intestinal mucosal barrier function [levels of diamine oxidase (DAO) and D-lactic acid, inflammatory markers (tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP), interleukin-8 (IL-8), interleukin-(IL-10)], and disease activity (intestinal mucosal lesion score, Mayo activity index score) were compared between the two groups before and after treatment.【Results】 Before treatment, there were no statistically significant differences in the indices between the two groups (P>0.05). After treatment, the observation group showed significantly shorter improvement times for bloating and diarrhea, as well as faster complete recovery of stool frequency and form compared to the control group (P<0.05). Additionally, the DAO, D-lactic acid, TNF-α, CRP, IL-8 levels, intestinal mucosal lesion score, and Mayo activity index score in the observation group were significantly lower than those in the control group, while IL-10 level in the observation group was higher than that in the control group (P<0.05).【Conclusion】 Mesalazine combined with compound glutamine significantly optimizes colonic function and disease activity in UC patients, improves intestinal mucosal barrier function, and reduces inflammation markers.

Key words： Colitis, Ulcerative Mesalamine Glutamine Treatment Outcome

收稿日期: 2024-06-26

中图分类号:

R574.62

引用本文:

黄鹏, 梁晴晴, 王明超. 美沙拉嗪联合复方谷氨酰胺治疗溃疡性结肠炎的疗效[J]. 医学临床研究, 2025, 42(3): 441-443.
HUANG Peng, LIANG Qingqing, WANG Mingchao. The Efficacy of Mesalazine Combined with Compound Glutamine in the Treatment of Ulcerative Colitis. JOURNAL OF CLINICAL RESEARCH, 2025, 42(3): 441-443.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2025.03.021 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2025/V42/I3/441

[1] 王帅,杨跃辉,李闯闯,等. 布拉氏酵母菌散联合美沙拉嗪治疗溃疡性结肠炎患者的治疗效果[J].中国临床药理学杂志,2023,39(16):2320-2324.
[2] 李俐,李丹,秦瑶,等. 柳氮磺吡啶联合复方谷氨酰胺治疗溃疡性结肠炎的临床疗效及对血清降钙素原和C反应蛋白的影响[J].中国肛肠病杂志,2023,43(2):23-25.
[3] 刘坤,徐菁,马竹芳,等. 复方谷氨酰胺联合美沙拉嗪对溃疡性结肠炎患者炎症状况及凝血功能的影响[J].河北医药,2023,45(11):1710-1712.
[4] 中华中医药学会. 溃疡性结肠炎诊疗指南[J].中国中医药现代远程教育,2011,9(10):126-128.
[5] 沈骏,冉志华,童锦禄,等. 炎症性肠病内镜分级和评分标准的一致性研究[J].中华消化内镜杂志,2008,25(5):239-244.
[6] 杨晓燕,周丽莎,董帜,等. 活动期溃疡性结肠炎MSCT表现与Mayo评分的相关性[J].临床放射学杂志,2015,34(10):1594-1597.
[7] 杨杰.化瘀清肠方治疗活动期溃疡性结肠炎疗效及对炎症因子、凝血功能和肠黏膜屏障功能的影响[J].现代中西医结合杂志,2023,32(9):1256-1259.
[8] 陈福安,蔡照华,张呈,等. 美沙拉嗪长期治疗溃疡性结肠炎患者的效果及对结肠黏膜癌相关基因表达的影响[J].中国医药,2022,17(6):876-880.
[9] 吴娜,李多,崔利军,等. 美沙拉嗪联合双歧杆菌活菌对溃疡性结肠炎患者疗效、炎性因子、肠道菌群及粪便相关因子的影响[J].临床误诊误治,2021,34(10):20-24.
[10] 王玲.奥曲肽联合金双歧治疗新生儿坏死性小肠结肠炎的临床效果及对炎性因子和胃肠功能的影响[J].中外医学研究,2020,18(36):42-44.
[11] 蒋世芳,曹立军,贺学强,等. 美沙拉嗪联合昂丹司琼对溃疡性结肠炎患者肠黏膜屏障功能及炎症因子水平的影响[J].中国医药,2023,18(8):1211-1215.
[12] 陈林. 复方谷氨酰胺联合美沙拉嗪治疗溃疡性结肠炎的效果及其抗炎机制[J].临床与病理杂志,2023,43(3):461-468.
[13] 潘智,邵赛丹,黄登,等. 虎地肠溶胶囊联合奥沙拉嗪对慢性溃疡性结肠炎患者肠黏膜病变、血清炎性因子及NGAL和MMP-9表达影响[J].浙江医学,2021,43(21):2337-2340.